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Abstract Live oral rotavirus (RV) vaccines are part of
routine childhood immunization but are associated with
adverse effects, particularly intussusception. We have de-
veloped a non-live combined RV – norovirus (NoV) vac-
cine candidate consisting of human RV inner-capsid rVP6
protein and NoV virus-like particles. To determine the
effect of delivery route on induction of VP6-specific pro-
tective immunity, BALB/c mice were administered a vac-
cine containing RV rVP6 intramuscularly, intranasally or a
combination of both, and challenged with murine RV. At
least 65 % protection against RV shedding was observed
regardless of delivery route. The levels of post-challenge
serum VP6-specific IgA titers correlated with protection.
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Rotavirus (RV) causes severe gastroenteritis in infants and
children under 5 years of age with high mortality and
morbidity rates [1]. Currently, two live oral RV vaccines,
the monovalent Rotarix (GlaxoSmithKline) and the pen-
tavalent Rotateq (Merck), are licensed and used exten-
sively [2, 3]. However, these oral vaccines are less
efficacious in developing countries [4, 5] and are associated
with safety concerns such as a risk of intussusception [6].
Non-live subunit RV vaccines are therefore considered as
alternatives for RV immunization.
Correlates of protection against RV infection are not
fully understood. Type-specific neutralizing antibodies
against the external proteins VP4 and VP7 have a role in
protective immunity after natural RV infection [7, 8], but
their role in vaccine-induced protective immunity against
severe RV gastroenteritis has not been shown. Although
serum anti-RV antibody IgA titers as a correlate of pro-
tection have been disputed [9], the best surrogate marker for
RV vaccine-induced protection appears to be a high level of
serum RV IgA antibody targeted to the inner capsid protein
VP6 [10, 11], which determines viral group (A-H) and
subgroup (SGI, II, I?II, non-I/II for group A) specificity
[12] and is highly conserved [13], immunogenic [14, 15]
and the most abundant RV protein [12]. VP6 does not in-
duce classical neutralizing antibodies, but it induces
heterotypic cross-reactive protection in mice [16–18].
Norovirus (NoV) is another leading cause of acute gas-
troenteritis in children, with genogroups GI and GII being
responsible for the majority of NoV cases [19]. For protec-
tion against childhood gastroenteritis, we have introduced a
concept of vaccination against RV and NoV with a com-
bined trivalent vaccine consisting of RV rVP6 protein and
NoV GI.3 and GII.4 virus-like particles (VLPs) [20]. We
have previously shown that a candidate combination vaccine
delivered intramuscularly (IM) to mice was highly im-
munogenic [20], and intranasal (IN) immunization protected
mice against murine RV challenge [21]. Delivery require-
ments for the NoV components in the induction of protective
NoV immune response were published recently [22]. In this
work, we compared IM and IN delivery and the combination
of both for induction of VP6-specific protective immunity
against RV challenge, and we examined humoral immune
responses for correlation with protection.
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Human RV rVP6 protein (SGII) used for immunization
and as antigen in ELISA was produced using a baculovirus
expression system in Sf9 insect cells [23]. The trivalent
RV-NoV combination vaccine was prepared by mixing the
rVP6 tubules and NoV GI.3 and GII.4 VLPs in equal
amounts [20].
Female 7-week-old BALB/c OlaHsd mice (5
mice/group) (Harlan, Horst, The Netherlands) were im-
munized IM or IN twice (at study weeks 0 and 3) with the
trivalent vaccine containing 10 lg or RV rVP6 per im-
munization point. Moreover, sequential IM and IN immu-
nizations (4 mice/group) with 10 lg of rVP6 alone were
performed to determine whether administration at two
distinct sites would enhance protection. No external adju-
vants were used. Naı¨ve mice receiving PBS served as
controls. Pre-immune (week 0) and pre-challenge (week 5)
tail blood samples of individual mice were collected, pro-
cessed to obtain sera and diluted 1:100 in PBS. At week 6,
mice were challenged orally with 1 9 104 focus-forming
units (FFU) (100 times the diarrheal dose DD50) of the
murine RV strain EDIMwt (SG non-I/II, G3P10[16]),
originally obtained from Dr. Ward (Gamble Institute of
Medical Research, Cincinnati, OH). Fecal samples were
collected prior to challenge (day 0) and daily for 8 days
(days 1-8) after the challenge. Mice were euthanized at day
8, when whole blood samples were also collected. The
protocol for the study (permission number 167-2010) was
approved by the Bioethics Committee of the Instituto de
Biotecnologia (Universidad Nacional Auto´noma de
Me´xico).
RV VP6-specific pre- and post-challenge antibody re-
sponses were determined by measuring levels of anti-VP6
IgG and IgA in individual sera at 1:100 and two-fold di-
lution series by ELISA according to previously published
procedures [20, 21].
The presence of RV antigen in fecal samples was de-
termined using an antigen ELISA [16]. Fecal antigen
shedding was expressed as the net OD405 value (the OD of
the pre-challenge fecal sample subtracted from the OD of
the post-challenge samples of the individual mouse).
The pre-immune sera of all mice were negative for anti-
VP6 IgG and IgA (data not shown). Robust systemic IgG
responses were induced by each immunization route
(Fig. 1a). Geometric mean titers (GMTs) of serum IgG
achieved by the IM, IN and IM?IN routes were equivalent
(p = 0.663). IN and IM?IN delivery elicited detectable
IgA antibodies (p = 0.556), while IM immunization did
not (Fig. 1b). No anti-VP6 antibodies were detected in sera
of control mice prior to the challenge (Fig. 1a and b).
The quantity of RV antigen shed in fecal samples was
determined up to 8 days post-challenge (Fig. 2a). A sig-
nificant difference in viral shedding was detected between
the mice immunized IM, IN and IM?IN and the control
mice (p = 0.011), whereas the shedding between the im-
munized groups was not different (p = 0.514). The total
antigen shedding of mice immunized IM and IN decreased
66 % (±12 %) and 65 % (±18 %) compared to the con-
trols (Fig. 2a and b). Although sequential IM?IN immu-
nization conferred a numerically higher protection rate
(84 ± 5 %) (Fig. 2b), it was not statistically different from
the groups immunized IM or IN.
No correlation of pre-challenge titers of IgG
(r = -0.455, p = 0.127) or IgA (r = -0.198, p = 0.497)
antibodies with protection rates was detected. After the RV
challenge, VP6-specific serum IgG and IgA antibody titers
increased in all VP6-immunized mice (Fig. 1a and b), but
only the levels of the post-challenge IgA increased sig-
nificantly compared to the pre-challenge levels (p\ 0.03).
Protection levels correlated with the levels of serum IgA
after the challenge (r = 0.607, p = 0.006). Following the
challenge, control mice also developed low levels of IgG
Fig. 1 Pre- and post-challenge VP6-specific IgG (a) and IgA
(b) antibodies in sera of individual mice immunized IM and IN with
the trivalent vaccine containing rVP6 (5 mice/group) or sequentially
IM?IN with rVP6 (4 mice/group). A sample was considered ELISA
positive if the optical density at 490 nm (OD490) was above the set
cutoff value (mean OD490 of control mice ? 3 9 SD) and C0.1. All
control mice were combined (8 mice/group). Endpoint titers of
individual mice, expressed as log10 of the reciprocal of the highest
sample dilution giving a positive reading, as well as geometric mean
titers of the groups (———) at study weeks 5 (pre-challenge tail-
blood sample) and 7 (post-challenge termination sera) are shown. A
titer of 50 was assigned for all negative samples, being a half of the
starting serum dilution. The statistical differences between non-
parametric observations of independent groups were assessed by
Mann-Whitney U-test (SPSS Inc, Chicago, IL); p B 0.05 was
considered to indicate a statistically significant difference
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(GMT B 2.5 log10) and IgA (GMT 2 log10), but the titers
were significantly lower than those of the vaccinated mice
(p\ 0.001).
RV VP6 has been proposed as a subunit vaccine can-
didate against RV by us [14, 20, 21, 23] and others [17]. It
forms different oligomeric structures in vitro [24], which
are highly immunogenic in mice without the need for ex-
ternal adjuvants [14, 20, 21, 25]. Due to the repetitive
multivalent antigenic structures, these oligomers are able to
cross-link B-cell receptors very efficiently [26], whereas
soluble VP6 generally requires an adjuvant for induction of
an immune response [17]. Although the role of VP6 in
protective immunity is still unclear, VP6 may be sufficient
for protective immunity, as induction of protection against
RV infection in mice and rabbits has been achieved with
inactivated double-layered (dl) RV particles [27], dl2/6-
VLPs [28] and VP6 protein [17, 21, 25] without the surface
VP4 and VP7 antigens. Unlike the surface proteins, anti-
bodies to the inner capsid VP6 are non-neutralizing.
However, anti-VP6 IgA, but not IgG, is able to inhibit RV
replication intracellularly [18, 29].
Human RV-derived rVP6 protein given parenterally or
mucosally induced similar levels of protection against RV
EDIMwt infection. Protection was evaluated in an adult
mouse model, which is an infection model but not a disease
model, by measuring reduction in fecal RV antigen shed-
ding after viral challenge [30]. Immunized mice showed
significant reduction ([65 %) in virus shedding when
compared to the controls. The protection was incomplete
but of the order of magnitude that is achieved against any
RV disease in humans after live RV vaccination. These
results indicate efficacy of the rVP6-based vaccine in
conferring protective immunity against live RV challenge
independently of the delivery route. Similar reduction rates
were previously published for mice immunized subcuta-
neously with rVP6 tubules [25]. Partial protection was also
achieved with inactivated dl RV particles [27] and VP6
DNA vaccines after IM administration [31]. Protection
close to 100 % against shedding of two murine RV strains
has been elicited after IN immunization with MBP-VP6
only after inclusion of an external adjuvant [17].
Although intestinal IgA was shown to be critical for RV
clearance and protection in the mouse model [32], serum
RV IgA targeted to VP6 has been considered the best
surrogate marker for vaccine-induced protection in humans
[10, 11]. We detected a positive correlation between post-
challenge VP6-specific serum IgA levels and the RV pro-
tection rate in mice. Both parenteral and mucosal delivery
induced similar clearance of RV, even though only the IN
and IM?IN routes led to detectable pre-challenge serum
IgA antibodies. IM immunized mice may have had unde-
tectable pre-existing serum IgA level, which expanded
rapidly after viral replication in the gut [33]. Viral repli-
cation possibly led to a significant increase in serum IgA
titers in VP6-primed mice, which correlated with reduction
in RV antigen shedding and therefore protection. However,
evidence of a correlation of serum IgA with protection has
been contradictory in animal models [34]. By contrast,
correlation of protection with serum IgA has been pre-
sented in mice following IN immunization with dl2/6-
VLPs and cholera toxin [28].
In conclusion, the human RV rVP6 protein induced
considerable protection in mice against live heterologous
RV challenge, independently of the immunization route.
These results highlight the importance of non-serotype-
specific antibody responses induced using the highly con-
served VP6 protein in heterotypic protection.
Acknowledgments We gratefully acknowledge the technical as-
sistance given by the laboratory personnel of the Vaccine Research
Center of University of Tampere Medical School and the Animal
Facility of Instituto de Biotecnologı´a (Universidad Nacional
Auto´noma de Me´xico).
Fig. 2 Protection against RV shedding in immunized mice. Viral
shedding curves (OD405 versus day post-challenge) for each animal
were plotted and the reduction in viral load was calculated by
comparing the mean area under the shedding curve of the immunized
mice to the mean area under the curve of the controls. a. Viral
shedding curves of experimental groups. Each point represents the
daily average of antigen shed per group with standard error of the
mean. Asterisks (*) indicate a significant difference (p B 0.05; Mann-
Whitney U-test) in daily shedding between the immunized and
control mice. b. Reductions in virus shedding of VP6-immunized
mice following challenge. Mean percent reductions of the experimen-
tal groups with standard error of the means are shown. A [50 %
reduction in virus shedding was considered significant protection
from virus challenge, as reported previously
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